Armistice Capital, LLC Reports New 6.93% Stake in Rigel Pharmaceuticals, Inc. (RIGL)

On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G regarding their holdings in Rigel Pharmaceuticals, Inc. (RIGL). The filing discloses that as of March 31, 2026, the reporting persons beneficially own 1,280,000 shares of common stock, representing a 6.93% ownership stake in the company. This represents a new position for the filer, as previous ownership was reported at zero. Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Under the terms of their investment management agreement, Armistice Capital exercises shared voting and dispositive power over the securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. The principal business office for the reporting persons is located in New York, New York.